MARKET

VTVT

VTVT

Vtv Therapeutics
NASDAQ
23.80
+0.71
+3.07%
After Hours: 22.87 -0.93 -3.91% 18:28 03/27 EDT
OPEN
22.20
PREV CLOSE
23.09
HIGH
23.82
LOW
22.03
VOLUME
23.31K
TURNOVER
0
52 WEEK HIGH
39.60
52 WEEK LOW
7.38
MARKET CAP
71.64M
P/E (TTM)
-2.4505
1D
5D
1M
3M
1Y
5Y
Viking Therapeutics gains on early data for oral weight loss therapy
Seeking Alpha · 2d ago
Weekly Report: what happened at VTVT last week (0318-0322)?
Weekly Report · 2d ago
Weekly Report: what happened at VTVT last week (0311-0315)?
Weekly Report · 03/18 12:25
vTv Therapeutics Appoints Anne Phillips, Reshuffles Board Committees
Anne Phillips has joined vTv Therapeutics, Inc. As a new independent director. She will also lead the Compensation Committee and serve on the Audit Committee. VTVT stock is down 10% in the last week. The company's stock price has risen to $7.
TipRanks · 03/14 12:12
vTv Therapeutics Q4 EPS $(1.67) Up From $(2.28) YoY
Benzinga · 03/13 12:03
VTv Therapeutics: Q4 Earnings Snapshot
VTv Therapeutics Inc. On Wednesday reported a loss of $3.5 million in its fourth quarter. The High Point, North Carolina-based company said it had a Loss of $1.67 per share. For the year, the company reported a losses of $20.3 million.
Barchart · 03/13 07:23
Weekly Report: what happened at VTVT last week (0304-0308)?
Weekly Report · 03/11 12:20
12 Health Care Stocks Moving In Tuesday's After-Market Session
NKGen Biotech (NASDAQ:NKGN) stock increased by 62.4% to $1.4 during Tuesday's after-market session. VTv Therapeutics stock moved upwards by 13.17%. Cerus ( NASDAQ:CERS) increased by 9.09% during the day. The company's, Q4 earnings came out today.
Benzinga · 03/05 21:31
More
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes HPP593, Nrf2/Bach1 Modulator Program, Azeliragon and HPP3033.

Webull offers vTv Therapeutics Inc stock information, including NASDAQ: VTVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTVT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VTVT stock methods without spending real money on the virtual paper trading platform.